Market Cap 1.77B
Revenue (ttm) 178.96M
Net Income (ttm) -159.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.12%
Debt to Equity Ratio 0.00
Volume 2,696,800
Avg Vol 2,285,210
Day's Range N/A - N/A
Shares Out 151.92M
Stochastic %K 46%
Beta 1.79
Analysts Strong Sell
Price Target $11.62

Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 659 0067
Fax: 206 659 0667
Address:
1165 Eastlake Avenue East, Seattle, United States
WallStreetBuyDip
WallStreetBuyDip Jul. 1 at 1:03 AM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
1 · Reply
Treasury225
Treasury225 Jun. 27 at 8:15 PM
$ADPT WHAT IS EITHER THAT CLOSING VOLUME. 3.9 MILLION SHARES AT 11.79 ON THE CLOSE!!!
0 · Reply
TheLearnerEarner
TheLearnerEarner Jun. 27 at 3:42 PM
$ADPT ✅ Healthcare - Mid Cap - Momentum Trap F-Score: 5/9 🏦 Analysts: 8x buy rating 👨‍🔬 Potential: trading at approximately 73% below estimate of its fair value 💠 Range (12m) $3.30 - $12.43 💰 RSI: 77.86 (overbought) 📊 NEWSDESK (article idea is for ADPT only) 📰 https://finance.yahoo.com/news/makes-adaptive-biotechnologies-adpt-buy-160002614.html
0 · Reply
Sunny8393284923
Sunny8393284923 Jun. 26 at 7:41 PM
0 · Reply
Sunny8393284923
Sunny8393284923 Jun. 26 at 7:41 PM
$ADPT absolute gem
0 · Reply
PenkeTrading
PenkeTrading Jun. 26 at 6:08 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Adaptive Biotechnologies Corp. Is that bullish or bearish? $ADPT #Adaptive #RsiOverbought #NASDAQ
0 · Reply
mankind1
mankind1 Jun. 26 at 1:16 PM
$ADPT something brewing
0 · Reply
healthcareguru
healthcareguru Jun. 25 at 5:50 PM
$ADPT massive overreaction to tiny/modest language change in NCCN guidelines…this is pretty much non-event. Fading the pop. 👎
0 · Reply
FeatherWeight
FeatherWeight Jun. 24 at 4:49 AM
$ADPT Bottomed ahead of S&P, higher lows, VCP footprint forming, ascending base, looks primed to breakout for good. On buy list. Price action wise looks like it currently has the lead over TEM, WGS, GH 😬 👀 🐎 group as a whole looking strong
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 1:00 PM
Craig-Hallum has updated their rating for Adaptive Biotechnologies ( $ADPT ) to Buy with a price target of 15.
0 · Reply
Latest News on ADPT
Top 3 Health Care Stocks That May Collapse This Quarter

Dec 11, 2024, 6:55 AM EST - 7 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

FNA NAMS


Adaptive Biotechnologies: Making Some Progress

Nov 26, 2024, 10:53 AM EST - 7 months ago

Adaptive Biotechnologies: Making Some Progress


Adaptive Announces Launch of Epic Integration for clonoSEQ®

Sep 13, 2023, 7:30 AM EDT - 1 year ago

Adaptive Announces Launch of Epic Integration for clonoSEQ®


WallStreetBuyDip
WallStreetBuyDip Jul. 1 at 1:03 AM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
1 · Reply
Treasury225
Treasury225 Jun. 27 at 8:15 PM
$ADPT WHAT IS EITHER THAT CLOSING VOLUME. 3.9 MILLION SHARES AT 11.79 ON THE CLOSE!!!
0 · Reply
TheLearnerEarner
TheLearnerEarner Jun. 27 at 3:42 PM
$ADPT ✅ Healthcare - Mid Cap - Momentum Trap F-Score: 5/9 🏦 Analysts: 8x buy rating 👨‍🔬 Potential: trading at approximately 73% below estimate of its fair value 💠 Range (12m) $3.30 - $12.43 💰 RSI: 77.86 (overbought) 📊 NEWSDESK (article idea is for ADPT only) 📰 https://finance.yahoo.com/news/makes-adaptive-biotechnologies-adpt-buy-160002614.html
0 · Reply
Sunny8393284923
Sunny8393284923 Jun. 26 at 7:41 PM
0 · Reply
Sunny8393284923
Sunny8393284923 Jun. 26 at 7:41 PM
$ADPT absolute gem
0 · Reply
PenkeTrading
PenkeTrading Jun. 26 at 6:08 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Adaptive Biotechnologies Corp. Is that bullish or bearish? $ADPT #Adaptive #RsiOverbought #NASDAQ
0 · Reply
mankind1
mankind1 Jun. 26 at 1:16 PM
$ADPT something brewing
0 · Reply
healthcareguru
healthcareguru Jun. 25 at 5:50 PM
$ADPT massive overreaction to tiny/modest language change in NCCN guidelines…this is pretty much non-event. Fading the pop. 👎
0 · Reply
FeatherWeight
FeatherWeight Jun. 24 at 4:49 AM
$ADPT Bottomed ahead of S&P, higher lows, VCP footprint forming, ascending base, looks primed to breakout for good. On buy list. Price action wise looks like it currently has the lead over TEM, WGS, GH 😬 👀 🐎 group as a whole looking strong
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 1:00 PM
Craig-Hallum has updated their rating for Adaptive Biotechnologies ( $ADPT ) to Buy with a price target of 15.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jun. 16 at 3:22 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
TenFolds
TenFolds Jun. 10 at 8:43 PM
Top 5 positions in my portfolio, with portfolio weighting and cost basis/share. $IDR 22%, $11. $IREN 21%, $10 $ENVX 14%, $9 $LUMN 11%, $3 $ADPT 11%, $5
2 · Reply
LIVE_Trading
LIVE_Trading Jun. 9 at 6:54 PM
$ADPT Could see bouncing on Support right here.👆$SPY $QQQ $NVDA $TSLA
0 · Reply
LIVE_Trading
LIVE_Trading Jun. 9 at 6:04 PM
$ADPT Could see bouncing on Support right here.👆$SPY $QQQ $NVDA $TSLA
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jun. 4 at 7:32 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Doozio
Doozio Jun. 4 at 1:07 PM
Almost as if all da April 🐑 fools sold in 🧠 May and went away. Whuts $YEXT is da gap n GOGO’s! These bums best $ADPT or be left behind waiting for that dip during 🐒🍌🧠⏰♾️
0 · Reply
Sunny8393284923
Sunny8393284923 Jun. 4 at 10:42 AM
$ADPT 👀
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:46 AM
$ADPT Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress Adaptive Biotechnologies announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma and chronic lymphocytic leukemia. "The breadth of new MRD evidence being shared across various blood cancer types at ASCO and EHA this year highlights the transformative impact MRD is having on clinical care and drug development," said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. "These data presentations are a testament to the central role that clonoSEQ MRD testing now plays in clinical management and drug development across lymphoid cancers, particularly when combined with several clonoSEQ data presentations in diffuse large B-cell lymphoma anticipated at the 18th International Conference on Malignant Lymphoma on June 17-21, 2025 in Lugano, Switzerland."
0 · Reply
ChessGM
ChessGM May. 28 at 1:48 AM
$ADPT https://open.substack.com/pub/chessgmstocks/p/top-10-holdings-from-biotech-hedge?r=2hmnhp&utm_campaign=post&utm_medium=web&showWelcomeOnShare=false .
0 · Reply
WallStreetBuyDip
WallStreetBuyDip May. 21 at 7:52 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
1 · Reply
TrendEdgeLogan
TrendEdgeLogan May. 21 at 4:46 PM
$ADPT keep an eye on this $1.40B mc FOUNDER-LED $XBI name here as pressure builds above rising 10/40/80-week SMAs just beneath key $10 level. Pct of all funds rose in most recent qtr to 1-year highs. Short squeeze underway as short float % continues to trend lower from 16.08% this time last year TrendEdge.app/asset/ADPT
1 · Reply
cowboybullride
cowboybullride May. 9 at 3:19 PM
$ADPT trending up for the past year, consistently beats earnings. This is an easy buy and hold play.
0 · Reply